Trevena Inc. said one of its lead new drug candidates, an experimental treatment for acute heart failure, failed to generate desired results in mid-stage clinical testing.
The disappointing study results caused the King of Prussia, Pa., company’s stock to close down 7.33 percent to $6.32 per share.
Trevena (NASDAQ: TRVN) officials said the company expects to focus its efforts going forward on oliceridine, a pain medicine in late-stage clinical testing, and on other new drug candidates in earlier-stage…
Trevena Inc. said one of its lead new drug candidates, an experimental treatment for acute heart failure, failed to generate desired results in mid-stage clinical testing.
The disappointing study results caused the King of Prussia, Pa., company’s stock to close down 7.33 percent to $6.32 per share.
Trevena (NASDAQ: TRVN) officials said the company expects to focus its efforts going forward on oliceridine, a pain medicine in late-stage clinical testing, and on other new drug candidates in earlier-stage…